Andrew Gvozdanovic, Felix Jozsa, Naomi Fersht, Patrick James Grover, Georgina Kirby, Neil Kitchen, Riccardo Mangiapelo, Andrew McEvoy, Anna Miserocchi, Rayna Patel, Lewis Thorne, Norman Williams, Michael Kosmin, Hani J Marcus
{"title":"将个性化移动健康(mHealth)应用程序集成到脑瘤患者的护理中:概念验证研究(IDEAL第1阶段)。","authors":"Andrew Gvozdanovic, Felix Jozsa, Naomi Fersht, Patrick James Grover, Georgina Kirby, Neil Kitchen, Riccardo Mangiapelo, Andrew McEvoy, Anna Miserocchi, Rayna Patel, Lewis Thorne, Norman Williams, Michael Kosmin, Hani J Marcus","doi":"10.1136/bmjsit-2021-000130","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Brain tumours lead to significant morbidity including a neurocognitive, physical and psychological burden of disease. The extent to which they impact the multiple domains of health is difficult to capture leading to a significant degree of unmet needs. Mobile health tools such as Vinehealth have the potential to identify and address these needs through real-world data generation and delivery of personalised educational material and therapies. We aimed to establish the feasibility of Vinehealth integration into brain tumour care, its ability to collect real-world and (electronic) patient-recorded outcome (ePRO) data, and subjective improvement in care.</p><p><strong>Design: </strong>A mixed-methodology IDEAL stage 1 study.</p><p><strong>Setting: </strong>A single tertiary care centre.</p><p><strong>Participants: </strong>Six patients consented and four downloaded and engaged with the mHealth application throughout the 12 weeks of the study.</p><p><strong>Main outcome measures: </strong>Over a 12-week period, we collected real-world and ePRO data via Vinehealth. We assessed qualitative feedback from mixed-methodology surveys and semistructured interviews at recruitment and after 2 weeks.</p><p><strong>Results: </strong>565 data points were captured including, but not limited to: symptoms, activity, well-being and medication. EORTC QLQ-BN20 and EQ-5D-5L completion rates (54% and 46%) were impacted by technical issues; 100% completion rates were seen when ePROs were received. More brain cancer tumour-specific content was requested. All participants recommended the application and felt it improved care.</p><p><strong>Conclusions: </strong>Our findings indicate value in an application to holistically support patients living with brain cancer tumours and established the feasibility and safety of further studies to more rigorously assess this.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/76/bmjsit-2021-000130.PMC9791405.pdf","citationCount":"0","resultStr":"{\"title\":\"Integration of a personalised mobile health (mHealth) application into the care of patients with brain tumours: proof-of-concept study (IDEAL stage 1).\",\"authors\":\"Andrew Gvozdanovic, Felix Jozsa, Naomi Fersht, Patrick James Grover, Georgina Kirby, Neil Kitchen, Riccardo Mangiapelo, Andrew McEvoy, Anna Miserocchi, Rayna Patel, Lewis Thorne, Norman Williams, Michael Kosmin, Hani J Marcus\",\"doi\":\"10.1136/bmjsit-2021-000130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Brain tumours lead to significant morbidity including a neurocognitive, physical and psychological burden of disease. The extent to which they impact the multiple domains of health is difficult to capture leading to a significant degree of unmet needs. Mobile health tools such as Vinehealth have the potential to identify and address these needs through real-world data generation and delivery of personalised educational material and therapies. We aimed to establish the feasibility of Vinehealth integration into brain tumour care, its ability to collect real-world and (electronic) patient-recorded outcome (ePRO) data, and subjective improvement in care.</p><p><strong>Design: </strong>A mixed-methodology IDEAL stage 1 study.</p><p><strong>Setting: </strong>A single tertiary care centre.</p><p><strong>Participants: </strong>Six patients consented and four downloaded and engaged with the mHealth application throughout the 12 weeks of the study.</p><p><strong>Main outcome measures: </strong>Over a 12-week period, we collected real-world and ePRO data via Vinehealth. We assessed qualitative feedback from mixed-methodology surveys and semistructured interviews at recruitment and after 2 weeks.</p><p><strong>Results: </strong>565 data points were captured including, but not limited to: symptoms, activity, well-being and medication. EORTC QLQ-BN20 and EQ-5D-5L completion rates (54% and 46%) were impacted by technical issues; 100% completion rates were seen when ePROs were received. More brain cancer tumour-specific content was requested. All participants recommended the application and felt it improved care.</p><p><strong>Conclusions: </strong>Our findings indicate value in an application to holistically support patients living with brain cancer tumours and established the feasibility and safety of further studies to more rigorously assess this.</p>\",\"PeriodicalId\":33349,\"journal\":{\"name\":\"BMJ Surgery Interventions Health Technologies\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2022-12-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/76/bmjsit-2021-000130.PMC9791405.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Surgery Interventions Health Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjsit-2021-000130\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Surgery Interventions Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjsit-2021-000130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Integration of a personalised mobile health (mHealth) application into the care of patients with brain tumours: proof-of-concept study (IDEAL stage 1).
Objectives: Brain tumours lead to significant morbidity including a neurocognitive, physical and psychological burden of disease. The extent to which they impact the multiple domains of health is difficult to capture leading to a significant degree of unmet needs. Mobile health tools such as Vinehealth have the potential to identify and address these needs through real-world data generation and delivery of personalised educational material and therapies. We aimed to establish the feasibility of Vinehealth integration into brain tumour care, its ability to collect real-world and (electronic) patient-recorded outcome (ePRO) data, and subjective improvement in care.
Design: A mixed-methodology IDEAL stage 1 study.
Setting: A single tertiary care centre.
Participants: Six patients consented and four downloaded and engaged with the mHealth application throughout the 12 weeks of the study.
Main outcome measures: Over a 12-week period, we collected real-world and ePRO data via Vinehealth. We assessed qualitative feedback from mixed-methodology surveys and semistructured interviews at recruitment and after 2 weeks.
Results: 565 data points were captured including, but not limited to: symptoms, activity, well-being and medication. EORTC QLQ-BN20 and EQ-5D-5L completion rates (54% and 46%) were impacted by technical issues; 100% completion rates were seen when ePROs were received. More brain cancer tumour-specific content was requested. All participants recommended the application and felt it improved care.
Conclusions: Our findings indicate value in an application to holistically support patients living with brain cancer tumours and established the feasibility and safety of further studies to more rigorously assess this.